

CURRICULUM VITAE: Martina Pennisi MD

Personal data

Age: 37 years

Place of birth: Milano, Italy

Citizenship: Italian

Languages: Italian (native speaker)

English (Proficient User)

French (Basic user)

Spanish (Basic user)

Current Work Address: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Via Venezzian 1, 20133, Milan - Italy
Phone: +39 02 2390 2835 /2072
Fax: +39 02 2390 3359 /2079
E-mail: martina.pennisi@istitutotumori.mi.it

Professional records:

Permanent position as Attending Physician of the Hematology and Bone Marrow Transplant Division at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan - Italy (Director: prof. Paolo Corradini).

Clinical organization of the diagnostic-therapeutic-assistance pathway for patients (inpatient and outpatient) suffering from oncohematological malignancies. In particular, in the context of autologous /allogeneic hematopoietic stem cell transplantation and cellular therapies with CAR-T.

Clinical and research experience:

- August 2020 – present: attending physician in the Hematology and Bone Marrow Transplantation Division at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano – Milan, Italy;
- December 2018 – July 2020: research visiting investigator at the Bone Marrow Transplant Service under the mentorship of Dr. Miguel-Angel Perales at Sloan-Kettering Institute for Cancer Research, New York, supported by a research grant from Università Statale degli Studi, Milan – Italy and a post-doc research fellowship of the American-Italian Cancer Foundation (August 2019 – July 2019)
- August 2013 – September 2018: resident in hematology (University of Milan):
 - January 2017 – September 2018:
 - inpatient care at the Hematology and Bone Marrow Transplantation Unit, Istituto Nazionale dei Tumori Milano (tutor Prof. Paolo Corradini): clinical management

- of lymphoma and multiple myeloma patients, high dose chemotherapy, autologous and allogeneic hematopoietic stem cell transplantation;
- clinical data collection and participation to design and conduct of retrospective and prospective observational and translational studies in lymphoma, myeloma and allogeneic hematopoietic stem cell transplantation fields;
- participation in the first clinical trials of CAR T cells in adult patients affected by Non-Hodgkin Lymphoma in Italy
- July 2016 – December 2016: Outpatient and inpatient care of patients affected by Thalassemias and other Congenital Anemias, and clinical data collection, at the Rare Diseases Unit, Division of Internal Medicine, IRCCS Fondazione Ca' Granda Policlinico, Milano (tutor Prof. Maria Domenica Cappellini)
- January 2016 – June 2016: Inpatient care of patients affected by Acute Myeloid and Lymphoid Leukemias and clinical data collection at the Hematology Division, Ospedale Niguarda Ca' Granda, Milano (tutor Dr. Roberto Cairoli)
- July 2015 – December 2015: Outpatient care in Haemostasis and Thrombosis at Hematology and Trasfusion Medicine Division, Ospedale Luigi Sacco, Milano (tutor Prof. Augusto Bramante Federici)
- February 2014 – June 2015: Outpatient care of patients affected by Multiple Myeloma and Lymphoma, and clinical data collection, at the Hematology and Bone Marrow Transplantation Unit, Istituto Nazionale dei Tumori Milano (tutor Prof. Paolo Corradini)
- August 2013 – February 2014: Inpatient care at the Internal Medicine Division, Ospedale San Paolo, Milano (tutor Dr. Massimo Zuin)
- February 2014 – September 2018: Involved in non-industry and industry-sponsored clinical trials conducted according to ICH-GCP (Latest TransCelerate GCP training on 30th January 2018)

Other professional activities:

- Directive Board Secretary of the Italian Society of Hematology - 2022 – 2024
- Search Coordinator for the IBMDR MI-03 transplant center at Fondazione IRCCS Istituto Nazionale dei Tumori since November 2022 (Search Coordinator Class Novembre 3rd 2022); trained for the use of the IBMDR software and for all procedures related to the search of matched unrelated donors
- Advanced Life Support (ALS), Italian Resuscitation Council (IRC), November 2021
- Didactic activity: tutoring of national and international medicine students during clinical activities; teaching classes in Master of Medical Biotechnology and Clinical Data Management at University of Milan

Education:

- September 6th 2018: National Board of Hematology, School of Medicine, University of Milan, Italy (evaluation: 70/70 cum Laude)
- Hematology residency delegate at “Residency Council” - Università Statale degli Studi di Milano - November 2015 – 2018
- August 2013 – September 2018: Resident Physician in Hematology Residency Program, University of Milan, Milan – Italy: 70/70 Magna cum laude
- February 2013 – July 2013: Attending Physician at Hematology and Bone Marrow Transplantation Unit at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
- March 27th 2013: Registered Member of the Official Medical Association of Milan, Italy (registration n: 43177)
- November 2012 – January 2013: Medical Professional License Training
- September 2006 – October 2012: School of Medicine, University of Milan, Milan – Italy: 110/110 Magna cum laude
- Other activities:
 - Exchange medical student at Universidade Federal do Estado do Rio de Janeiro, Brazil (UNIRIO) – February 2010

Publications:

- Deschênes-Simard X, **Pennisi M**, Perales MA, Shah GL, Zelenetz AD, Yahalom J, Imber BS, Santomaso BD, Dahi PB. Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma. *Leuk Lymphoma*. 2024 Nov 20:1-6. doi: 10.1080/10428194.2024.2430703. Online ahead of print.
- Shahid Z, Jain T, Dioverti V, **Pennisi M**, Mikkilineni L, Swetha Kambhampati Thiruvengadam, Shah NN, Dadwal S, Papanicolaou G, Hamadani M, Carpenter PA, Maron Alfaro G, Seo SK, Hill JA, Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies. *Transplantation and Cellular Therapy*. Vol 30, Issue 10, Oct 2024, 955-969. <https://doi.org/10.1016/j.jtct.2024.07.018>.
- Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, **Pennisi M**, Gauthier J, Shadman M, Gowda L, Mirza AS, Bilal Abid M, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Zhen-Huan Hu, Hai-Lin Wang, Baer A, Baro E, Miao H, Spooner C, Xu H, and Pasquini MC. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. *Blood* (2024) 143 (26): 2722–2734. <https://doi.org/10.1182/blood.2023023447>.
- Stella, F., Chiappella, A., Casadei, B., Bramanti, S., Ljevar, S., Chiusolo, P., Rocco, A.D., Tisi, M.C., Carrabba, M.G., Cutini, I., Martino, M., Doderò, A., Bonifazi, F.,

Santoro, A., Sorà, F., Botto, B., Barbui, A.M., Russo, D., Musso, M., Grillo, G., Krampera, M., Olivieri, J., Ladetto, M., Cavallo, F., Massaia, M., Arcaini, L., **Pennisi, M.**, Zinzani, P.L., Miceli, R., Corradini, P. A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas. (2024) *Blood Cancer Discovery*, 5 (5), pp. 318-330. DOI: 10.1158/2643-3230.BCD-24-0052.

- Locke, F.L., Siddiqi, T., Jacobson, C.A., Ghobadi, A., Ahmed, S., Miklos, D.B., Perales, M.-A., Munoz, J., Fingrut, W.B., **Pennisi, M.**, Gauthier, J., Shadman, M., Gowda, L., Mirza, A.-S., Abid, M.B., Hong, S., Majhail, N.S., Kharfan-Dabaja, M.A., Khurana, A., Badar, T., Lin, Y., Bennani, N.N., Herr, M.M., Hu, Z.-H., Wang, H.-L., Baer, A., Baro, E., Miao, H., Spooner, C., Xu, H., Pasquini, M.C. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. (2024) *Blood*, 143 (26), pp. 2722-2734. DOI: 10.1182/blood.2023023447
- Chiappella, A., Casadei, B., Chiusolo, P., Di Rocco, A., Ljevar, S., Magni, M., Angelillo, P., Barbui, A.M., Cutini, I., Doderò, A., Bonifazi, F., Tisi, M.C., Bramanti, S., Musso, M., Farina, M., Martino, M., Novo, M., Grillo, G., Patriarca, F., Zacchi, G., Krampera, M., **Pennisi, M.**, Galli, E., Martelli, M., Ferreri, A.J.M., Ferrari, S., Saccardi, R., Bermema, A., Guidetti, A., Miceli, R., Zinzani, P.L., Corradini, P. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. (2024) *Leukemia*, 38 (5), pp. 1107-1114. DOI: 10.1038/s41375-024-02213-x
- Doderò, A., Bramanti, S., Di Trani, M., **Pennisi, M.**, Ljevar, S., Chiappella, A., Massimo, M., Guidetti, A., Corrado, F., Nierychlewska, P.M., Di Rocco, A., Lorenzini, D., Daoud, R., De Philippis, C., Santoro, A., Carlo-Stella, C., Corradini, P. Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas. (2024) *British Journal of Haematology*, 204 (1), pp. 151-159. DOI: 10.1111/bjh.19057
- Stella, F., Marasco, V., Virginia Levati, G., Guidetti, A., De Filippo, A., **Pennisi, M.**, Vismara, C., Miceli, R., Ljevar, S., Tecchio, C., Mordini, N., Gobbi, G., Saracino, L., Corradini, P. Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial. (2023) *Blood Advances*, 7 (19), pp. 5996-6004. DOI: 10.1182/bloodadvances.2023010348.
- Guidetti, A., Doderò, A., Lorenzoni, A., Pizzamiglio, S., Argiroffi, G., Chiappella, A., Bagnoli, F., Marasco, V., Carniti, C., Monfrini, C., Seregini, E., **Pennisi, M.**, Verderio, P., Alessi, A., Corradini, P. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy. (2023) *Cancer*, 129 (2), pp. 255-263. DOI: 10.1002/cncr.34532.
- Riedell, P.A., Hwang, W.-T., Nastoupil, L.J., **Pennisi, M.**, McGuirk, J.P., Maziarz, R.T., Bachanova, V., Oluwole, O.O., Brower, J., Flores, O.A., Ahmed, N., Schachter, L., Bharucha, K., Dholaria, B.R., Schuster, S.J., Perales, M.-A., Bishop, M.R., Porter, D.L. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial

Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. (2022) *Transplantation and Cellular Therapy*, 28 (10), pp. 669-676. DOI: 10.1016/j.jtct.2022.07.011.

- Monfrini, C., Stella, F., Aragona, V., Magni, M., Ljevar, S., Vella, C., Fardella, E., Chiappella, A., Nanetti, F., **Pennisi, M.**, Dodero, A., Guidetti, A., Corradini, P., Carniti, C. Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma. (2022) *Clinical Cancer Research*, 28 (15), pp. 3378-3386. DOI: 10.1158/1078-0432.CCR-22-0164.
- Dodero, A., Guidetti, A., Marino, F., Tucci, A., Barretta, F., Re, A., Balzarotti, M., Monfrini, C.C.C., Chiappella, A., Cabras, A., Facchetti, F., **Pennisi, M.**, Rahal, D., Monti, V., Devizzi, L., Miceli, R., Cocito, F., Farina, L., Ricci, F., Rossi, G., Carlo-Stella, C., Corradini, P. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. (2022) *Haematologica*, 107 (5), pp. 1153-1162. DOI: 10.3324/haematol.2021.278638.
- Smith, M., Dai, A., Ghilardi, G., Amelsberg, K.V., Devlin, S.M., Pajarillo, R., Slingerland, J.B., Beghi, S., Herrera, P.S., Giardina, P., Clurman, A., Dwomoh, E., Armijo, G., Gomes, A.L.C., Littmann, E.R., Schluter, J., Fontana, E., Taur, Y., Park, J.H., Palomba, M.L., Halton, E., Ruiz, J., Jain, T., **Pennisi, M.**, Afuye, A.O., Perales, M.-A., Freyer, C.W., Garfall, A., Gier, S., Nasta, S., Landsburg, D., Gerson, J., Svoboda, J., Cross, J., Chong, E.A., Giral, S., Gill, S.I., Riviere, I., Porter, D.L., Schuster, S.J., Sadelain, M., Frey, N., Brentjens, R.J., June, C.H., Pamer, E.G., Peled, J.U., Facciabene, A., van den Brink, M.R.M., Ruella, M. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. (2022) *Nature Medicine*, 28 (4), pp. 713-723. DOI: 10.1038/s41591-022-01702-9.
- Alarcon Tomas, A., Whiting, K., Maloy, M., Ruiz, J.D., Devlin, S., Sanchez-Escamilla, M., Yañez, L., Castillo, N., **Pennisi, M.**, Cho, C., Shaffer, B., Castro-Malaspina, H., Klimek, V., Giral, S.A., Tamari, R., Perales, M.-A. The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. (2021) *Bone Marrow Transplantation*, 56 (11), pp. 2749-2754. DOI: 10.1038/s41409-021-01392-w.
- **Pennisi, M.**, Sanchez-Escamilla, M., Flynn, J.R., Shouval, R., Tomas, A.A., Silverberg, M.L., Batlevi, C., Brentjens, R.J., Dahi, P.B., Devlin, S.M., Diamonte, C., Giral, S., Halton, E.F., Jain, T., Maloy, M., Mead, E., Palomba, M.L., Ruiz, J., Santomaso, B., Sauter, C.S., Scordo, M., Shah, G.L., Park, J.H., San Segundo, L.Y., Perales, M.-A. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. (2021) *Blood Advances*, 5 (17), pp. 3397-3406. DOI: 10.1182/BLOODADVANCES.2020003885.

- Garcia-Recio, M., Wudhikarn, K., **Pennisi, M.**, Alonso-Trillo, R., Flynn, J., Shouval, R., Afuye, A.O., Silverberg, M.L., Batlevi, C.W., Dahi, P., Devlin, S., Giralt, S.A., Halton, E., Ruiz, J., Maloy, M., Mead, E., Palomba, M.L., Santomasso, B., Sauter, C.S., Scordo, M., Shah, G.L., Perales, M.-A. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. (2021) Transplantation and Cellular Therapy, 27 (3), pp. 233-240. Cited 30 times. DOI: 10.1016/j.jtct.2020.10.022.
- Lin, R.J., Lobaugh, S.M., **Pennisi, M.**, Chan, H.T., Batlevi, Y., Ruiz, J.D., Elko, T.A., Maloy, M.A., Batlevi, C.L., Dahi, P.B., Giralt, S.A., Hamlin, P.A., Mead, E., Noy, A., Palomba, M.L., Santomasso, B.D., Sauter, C.S., Scordo, M., Shah, G.L., Korc-Grodzicki, B., Kim, S.J., Silverberg, M.L., Brooklyn, C.A., Devlin, S.M., Perales, M.-A. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. (2021) Haematologica, 106 (1), pp. 255-258. DOI: 10.3324/haematol.2019.243246.
- Sermer, D., Batlevi, C., Lia Palomba, M., Shah, G., Lin, R.J., Perales, M.-A., Scordo, M., Dahi, P., **Pennisi, M.**, Afuye, A., Silverberg, M.L., Ho, C., Flynn, J., Devlin, S., Caron, P., Hamilton, A., Hamlin, P., Horwitz, S., Joffe, E., Kumar, A., Matasar, M., Noy, A., Owens, C., Moskowitz, A., Straus, D., von Keudell, G., Rodriguez-Rivera, I., Falchi, L., Zelenetz, A., Yahalom, J., Younes, A., Sauter, C. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. (2020) Blood Advances, 4 (19), pp. 4669-4678. DOI: 10.1182/bloodadvances.2020002118.
- Jain, T., Knezevic, A., **Pennisi, M.**, Chen, Y., Ruiz, J.D., Purdon, T.J., Devlin, S.M., Smith, M., Shah, G.L., Halton, E., Diamonte, C., Scordo, M., Sauter, C.S., Mead, E., Santomasso, B.D., Palomba, M.L., Batlevi, C.W., Maloy, M.A., Giralt, S., Smith, E., Brentjens, R., Park, J.H., Perales, M.-A., Mailankody, S. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. (2020) Blood Advances, 4 (15), pp. 3776-3787. DOI: 10.1182/bloodadvances.2020002509.
- Wudhikarn, K., Palomba, M.L., **Pennisi, M.**, Garcia-Recio, M., Flynn, J.R., Devlin, S.M., Afuye, A., Silverberg, M.L., Maloy, M.A., Shah, G.L., Scordo, M., Dahi, P.B., Sauter, C.S., Batlevi, C.L., Santomasso, B.D., Mead, E., Seo, S.K., Perales, M.-A. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. (2020) Blood Cancer Journal, 10 (8), art. no. 79. DOI: 10.1038/s41408-020-00346-7.
- Wudhikarn, K., **Pennisi, M.**, Garcia-Recio, M., Flynn, J.R., Afuye, A., Silverberg, M.L., Maloy, M.A., Devlin, S.M., Batlevi, C.L., Shah, G.L., Scordo, M., Palomba, M.L., Dahi, P.B., Sauter, C.S., Santomasso, B.D., Mead, E., Perales, M.-A. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. (2020) Blood Advances, 4 (13), pp. 3024-3033. DOI: 10.1182/bloodadvances.2020001972.

- Gutgarts, V., Jain, T., Zheng, J., Maloy, M.A., Ruiz, J.D., **Pennisi, M.**, Jaimes, E.A., Perales, M.-A., Sathick, J. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. (2020) *Biology of Blood and Marrow Transplantation*, 26 (6), pp. 1071-1076. DOI: 10.1016/j.bbmt.2020.02.012.
- **Pennisi, M.**, Jain, T., Santomaso, B.D., Mead, E., Wudhikarn, K., Silverberg, M.L., Batlevi, Y., Shouval, R., Devlin, S.M., Batlevi, C., Brentjens, R.J., Dahi, P.B., Diamonte, C., Giralt, S., Halton, E.F., Maloy, M., Palomba, M.L., Sanchez-Escamilla, M., Sauter, C.S., Scordo, M., Shah, G., Park, J.H., Perales, M.-A. Comparing CAR T-cell toxicity grading systems: Application of the ASTCT grading system and implications for management. (2020) *Blood Advances*, 4 (4), pp. 676-686. DOI: 10.1182/bloodadvances.2019000952.
- Sureda, A., **Pennisi, M.**, Corradini, P. Allogeneic transplantation for relapsed hodgkin lymphoma. (2020) *Hematologic Malignancies*, pp. 365-380. DOI: 10.1007/978-3-030-32482-7_21.
- Mussetti, A., Martinetti, N., Cieri, N., **Pennisi, M.**, Doderio, A., Corradini, P. Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. (2019) *Bone Marrow Transplantation*, 54 (8), pp. 1237-1244. DOI: 10.1038/s41409-018-0417-9.
- Zinzani, P.L., Santoro, A., Chiti, A., Lastoria, S., Pinto, A., Rigacci, L., Barosi, G., **Pennisi, M.**, Corradini, P. Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. (2019) *Leukemia and Lymphoma*, 60 (5), pp. 1204-1213. DOI: 10.1080/10428194.2018.1519808.
- Doderio, A., Guidetti, A., Tucci, A., Barretta, F., Novo, M., Devizzi, L., Re, A., Passi, A., Pellegrinelli, A., Pruneri, G., Miceli, R., Testi, A., **Pennisi, M.**, Di Chio, M.C., Matteucci, P., Carniti, C., Facchetti, F., Rossi, G., Corradini, P. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. (2019) *Leukemia*, 33 (4), pp. 1047-1051. DOI: 10.1038/s41375-018-0320-9.
- **Pennisi, M.**, Berchicci, L., Miserocchi, E., Mussetti, A., Cacioppo, V., David, A., Scialdone, A., Lorusso, I., Modorati, G., Corradini, P., Montefusco, V. Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment (2019) *Leukemia and Lymphoma*, 60 (2), pp. 477-482. DOI: 10.1080/10428194.2018.1480770.
- Mussetti, A., De Philippis, C., Carniti, C., Bastos-Oreiro, M., Gayoso, J., Cieri, N., **Pennisi, M.**, Ciceri, F., Greco, R., Peccatori, J., Patriarca, F., Mariotti, J., Castagna, L., Corradini, P. CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. (2018) *Bone Marrow Transplantation*, 53 (12), pp. 1522-1531. DOI: 10.1038/s41409-018-0183-8.
- Reda, G., Riva, M., Fattizzo, B., Cassin, R., Giannarelli, D., **Pennisi, M.**, Freyrie, A., Cairoli, R., Molteni, A., Cortelezzi, A. Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With

Myelodysplastic Syndromes or Acute Myeloid Leukemia. (2018) *Seminars in Hematology*, 55 (4), pp. 202-208. DOI: 10.1053/j.seminhematol.2018.02.005.

- Montefusco, V., Mussetti, A., Rezzonico, F., Maura, F., **Pennisi, M.**, De Philippis, C., Capecchi, M., Corradini, P. Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients. (2017) *Bone Marrow Transplantation*, 52 (12), pp. 1602-1608. DOI: 10.1038/bmt.2017.183.
- Roumi, J.E., Moukhadder, H.M., Graziadei, G., **Pennisi, M.**, Cappellini, M.D., Taher, A.T. Pregnancy in β -thalassemia intermedia at two tertiary care centers in Lebanon and Italy: A follow-up report on fetal and maternal outcomes. (2017) *American Journal of Hematology*, 92 (6), pp. E96-E99. DOI: 10.1002/ajh.24690.
- Maura, F., Guidetti, A., Pellegrielli, A., Doderò, A., **Pennisi, M.**, Caprioli, C., Testi, A., Farina, L., Bolli, N., Devizzi, L.F., Cabras, A., Corradini, P. High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. (2016) *Blood Cancer Journal*, 6 (11), art. no. e491. DOI: 10.1038/bcj.2016.99.
- Montefusco, V., Galli, M., Spina, F., Stefanoni, P., Mussetti, A., Perrone, G., De Philippis, C., Dalto, S., Maura, F., Bonini, C., Rezzonico, F., **Pennisi, M.**, Roncari, L., Soldarini, M., Doderò, A., Farina, L., Cocito, F., Caprioli, C., Corradini, P. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: Selective occurrence after lenalidomide, (2014) *Leukemia and Lymphoma*, 55 (9), pp. 2032-2037. DOI: 10.3109/10428194.2014.914203.

Abstracts:

- Oral presentation at the 2020 TCT meeting in the Immune and Gene Therapy I session. Abstr n. 51 “*Comparing Car T Cells Toxicities Grading Systems: Application of Astct Grading System and Implications for Management*”. Pennisi M, Jain T, Batlevi Y, Silverberg ML, Shouval R, Devlin S, Batlevi C, Brentjens R, Dahi P, Diamonte C, Flynn J, Giralt S, Halton E, Maloy M, Mead E, Palomba ML, Sanchez-Escamilla M1, Santomaso B, Sauter C, Scordo M, Shah G, Park J, Perales MA
- Poster presentation at the 2020 TCT meeting. Abstr n. 221 “*Don't Let the HCT-CI Fool You: Similar Outcomes with Myeloablative CD34+ Selected Allo-HCT Compared to Unmodified RIC Allo-HCT in Patients with AML or MDS and High Comorbidity Scores*”. Pennisi M, Cho C, Devlin SM, Ruiz J, Maloy MA, Alarcon Tomas A, Castillo Flores N, Lin R, Politikos I, Sanchez-Escamilla M, Scordo M, Shah G, Barker JN, Castro-Malaspina H, Gyurkocza B, Dahi PB, Jakubowski AA, Papadopoulos EB, Ponce DM, Shouval R, Sauter C, Shaffer B, Tamari R, Van den Brink MRM, Young JW, Giralt SA, Perales MA

- Poster presentation at the 61st ASH Annual Meeting & Exposition (ASH 2019) Abstr n. 4458 *“Comparing Grading of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management”*. Pennisi M, Jain T, Batlevi Y, Silverberg ML, Shouval R, Devlin S, Batlevi C, Brentjens R, Dahi P, Diamonte C, Flynn J, Giralto S, Halton E, Maloy M, Mead E, Palomba ML, Sanchez-Escamilla M1, Santomaso B, Sauter C, Scordo M, Shah G, Park J, Perales MA
- Poster presentation at the 61st ASH Annual Meeting & Exposition (ASH 2019) Abstr n. 1947 *“Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells”*. Pennisi M, Sanchez-Escamilla M, Flynn J, Shouval R, Batlevi Y, Silverberg ML, Batlevi C, Brentjens R, Dahi P, Devlin S, Diamonte C, Giralto S, Halton E, Jain T, Maloy M, Mead E, Palomba L, Santomaso B, Sauter C, Scordo M, Shah G, Park J, Perales AM
- Poster presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018) Abstr n. A-947-0015-00812 *“Early toxicities following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide”*. Pennisi M, Mussetti A, Sciumbata VM, Perrone G, Corradini P

I authorize the use of my personal data in compliance with Legislative Decree 196/03 and EU regulation 679/2016 (GDPR).

Milan, 25/11/2024

Dr. Martina Pennisi